Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Pulse Biosciences (PLSE) Share Price

Media stories about Pulse Biosciences (NASDAQ:PLSE) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pulse Biosciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.4800860124006 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several research analysts have recently issued reports on PLSE shares. BidaskClub cut Pulse Biosciences from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. ValuEngine raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.

Shares of Pulse Biosciences traded up $0.43, hitting $15.89, on Monday, MarketBeat reports. The company’s stock had a trading volume of 48,505 shares, compared to its average volume of 147,191. Pulse Biosciences has a 12 month low of $9.81 and a 12 month high of $39.50.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, May 8th. The company reported ($0.51) EPS for the quarter.

In other news, Director Robert W. Duggan purchased 21,353 shares of Pulse Biosciences stock in a transaction dated Friday, May 11th. The stock was purchased at an average cost of $23.16 per share, for a total transaction of $494,535.48. Following the transaction, the director now directly owns 5,862,422 shares of the company’s stock, valued at $135,773,693.52. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 39.30% of the stock is owned by insiders.

About Pulse Biosciences

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply